Literature DB >> 10781591

Purification and molecular cloning of a novel essential component of the apolipoprotein B mRNA editing enzyme-complex.

H Lellek1, R Kirsten, I Diehl, F Apostel, F Buck, J Greeve.   

Abstract

Editing of apolipoprotein B (apoB) mRNA requires the catalytic component APOBEC-1 together with "auxiliary" proteins that have not been conclusively characterized so far. Here we report the purification of these additional components of the apoB mRNA editing enzyme-complex from rat liver and the cDNA cloning of the novel APOBEC-1-stimulating protein (ASP). Two proteins copurified into the final active fraction and were characterized by peptide sequencing and mass spectrometry: KSRP, a 75-kDa protein originally described as a splicing regulating factor, and ASP, a hitherto unknown 65-kDa protein. Separation of these two proteins resulted in a reduction of APOBEC-1-stimulating activity. ASP represents a novel type of RNA-binding protein and contains three single-stranded RNA-binding domains in the amino-terminal half and a putative double-stranded RNA-binding domain at the carboxyl terminus. Purified recombinant glutathione S-transferase (GST)-ASP, but not recombinant GST-KSRP, stimulated recombinant GST-APOBEC-1 to edit apoB RNA in vitro. These data demonstrate that ASP is the second essential component of the apoB mRNA editing enzyme-complex. In rat liver, ASP is apparently associated with KSRP, which may confer stability to the editing enzyme-complex with its substrate apoB RNA serving as an additional auxiliary component.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10781591     DOI: 10.1074/jbc.M001786200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  65 in total

Review 1.  The challenge of target sequence specificity in C-->U RNA editing.

Authors:  Nicholas O Davidson
Journal:  J Clin Invest       Date:  2002-02       Impact factor: 14.808

2.  APOBEC3 proteins and genomic stability: the high cost of a good defense.

Authors:  Iñigo Narvaiza; Sébastien Landry; Matthew D Weitzman
Journal:  Cell Cycle       Date:  2012-01-01       Impact factor: 4.534

3.  The cytidine deaminases AID and APOBEC-1 exhibit distinct functional properties in a novel yeast selectable system.

Authors:  Kristina Krause; Kenneth B Marcu; Jobst Greeve
Journal:  Mol Immunol       Date:  2005-06-15       Impact factor: 4.407

4.  ZBP2 facilitates binding of ZBP1 to beta-actin mRNA during transcription.

Authors:  Feng Pan; Stefan Hüttelmaier; Robert H Singer; Wei Gu
Journal:  Mol Cell Biol       Date:  2007-09-24       Impact factor: 4.272

5.  Mechanism for APOBEC3G catalytic exclusion of RNA and non-substrate DNA.

Authors:  William C Solomon; Wazo Myint; Shurong Hou; Tapan Kanai; Rashmi Tripathi; Nese Kurt Yilmaz; Celia A Schiffer; Hiroshi Matsuo
Journal:  Nucleic Acids Res       Date:  2019-08-22       Impact factor: 16.971

6.  Mouse and other rodent models of C to U RNA editing.

Authors:  Valerie Blanc; Nicholas O Davidson
Journal:  Methods Mol Biol       Date:  2011

7.  Hippocampal Characteristics and Invariant Sequence Elements Distribution of GLRA2 and GLRA3 C-to-U Editing.

Authors:  Philipp Schaefermeier; Sarah Heinze
Journal:  Mol Syndromol       Date:  2016-12-16

8.  Differentiation-induced colocalization of the KH-type splicing regulatory protein with polypyrimidine tract binding protein and the c-src pre-mRNA.

Authors:  Megan P Hall; Sui Huang; Douglas L Black
Journal:  Mol Biol Cell       Date:  2003-12-02       Impact factor: 4.138

9.  A survey of genomic traces reveals a common sequencing error, RNA editing, and DNA editing.

Authors:  Alexander Wait Zaranek; Erez Y Levanon; Tomer Zecharia; Tom Clegg; George M Church
Journal:  PLoS Genet       Date:  2010-05-20       Impact factor: 5.917

10.  The expression of apoB mRNA editing factors is not the sole determinant for the induction of editing in differentiating Caco-2 cells.

Authors:  Chad A Galloway; Harold C Smith
Journal:  Biochem Biophys Res Commun       Date:  2009-11-20       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.